Testosterone Levels and Quality of Life in Diverse Male Patients With Cancers Unrelated to Androgens

Fleishman, Stewart B.; Khan, Hina; Homel, Peter; Suhail, M. F.; Strebel-Amrhein, Rotraud; Mohammad, Farhan; Mahajan, Divya; Rosenwald, Victoria; Guarino, Michael J.; Mirzoyev, T.; Wozniak, Timothy F.; Suppiah, K.

doi:10.1200/jco.2010.30.3818

Cited by 26 publications

(24 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, similarly high scores have been reported for Caucasian men 24 months post-diagnosis who received either radical prostatectomy or external beam radiation therapy (FACT-P mean = 128, SD = 17.1) [18]; and in Japanese patients treated with carbon ion therapy 12 months after treatment (FACT-P mean = 120.4 (SD = 21.1) [19]. Our sample showed similar variability to that reported in other studies [20][21][22].…”

Section: Discussionsupporting

confidence: 87%

Evaluation of an informational pamphlet on distress and perceptions of supportive care for men with prostate cancer

PreydeMichèle

Hatton-BauerJane

CunninghamCraig

et al. 2012

Journal of Men's Health

View full text Add to dashboard Cite

Background: Many men with prostate cancer experience elevated levels of anxiety and distress which may interfere with their quality of life. Furthermore, there are challenges to providing supportive care in regional centers such as transportation difficulties. The purpose of this collaborative research project was to evaluate an informational pamphlet, and explore self-ratings of various emotional symptoms and optimal ways to provide psychosocial oncology to men with prostate cancer in a regional cancer centre. Methods: Men with prostate cancer accessing medical treatment were invited to complete a survey about their emotional experiences and completed a quality of life measure. These men were given an informational pamphlet on distress, and were contacted approximately three weeks later to evaluate the pamphlet and the quality of life measure was re-administered. Qualitative comments on supportive care were elicited. Results: Sixty-four men participated in the initial survey and 50 (78%) completed the evaluation of the pamphlet. The pamphlet was reported to be easy to read and contained useful information, though men would have preferred to receive this information at an earlier time. Distress and quality of life scores were similar to other samples of men with prostate cancer, and there were no statistically significant differences in quality of life scores for patients receiving radiation (n = 44) compared to the other types (n = 15) of medical treatment (F (1, 57) = 0.610, P < 0.438). Of the emotional symptoms, ''worry'' and ''anxiety'' were rated as most problematic and ''distress'' as least problematic. Conclusions: Overall, participants rated the pamphlet as very good, though improvements in content and timing are warranted. While many men did not report high levels of distress, there remains a concern for a few patients with elevated levels of distress and patients who expressed difficulty accessing counselling support.

show abstract

Section: Discussionsupporting

confidence: 87%

Evaluation of an informational pamphlet on distress and perceptions of supportive care for men with prostate cancer

PreydeMichèle

Hatton-BauerJane

CunninghamCraig

et al. 2012

Journal of Men's Health

View full text Add to dashboard Cite

show abstract

“…There is high prevalence of testosterone deficiency in men with cancer which can occur either before or after chemo/radiotherapy . A study of 428 men with non‐testosterone related cancers found that the prevalence of hypogonadism was 48% based on TT and 78% on fT measurement in men with non‐testosterone related cancers . Low testosterone occurred independently of cancer type, stage, weight loss and the use of chemotherapeutic or opioid drugs .…”

Section: Testosterone and Cancermentioning

confidence: 99%

Testosterone and mortality

Muraleedharan

Jones

2014

Clinical Endocrinology

View full text Add to dashboard Cite

SummaryEpidemiological studies have found that men with low or low normal endogenous testosterone are at an increased risk of mortality than those with higher levels. Cardiovascular disease accounts for the greater proportion of deaths in those with low testosterone. Cancer and respiratory deaths in some of the studies are also significantly more prevalent. Diseasespecific studies have identified that there are higher mortality rates in men with cardiovascular, respiratory and renal diseases, type 2 diabetes and cancer with low testosterone. Obesity, metabolic syndrome, type 2 diabetes, cardiovascular disease and inflammatory disorders are all associated with an increased prevalence of testosterone deficiency. Two major questions that arise from these findings are (1) is testosterone deficiency directly involved in the pathogenesis of these conditions and/or a contributory factor impairing the body's natural defences or is it merely a biomarker of ill health and the severity of underlying disease process? (2) Does testosterone replacement therapy retard disease progression and ultimately enhance the clinical prognosis and survival? This review will discuss the current state of knowledge and discuss whether or not there are any answers to either of these questions. There is convincing evidence that low testosterone is a biomarker for disease severity and mortality. Testosterone deficiency is associated with adverse effects on certain cardiovascular risk factors that when combined could potentially promote atherosclerosis. The issue of whether or not testosterone replacement therapy improves outcomes is controversial. Two retrospective studies in men with diagnosed hypogonadism with or without type 2 diabetes have reported significantly improved survival.

show abstract

“…Low testosterone in cancer patients has been correlated with fatigue, sexual disinterest, and decreased quality of life 30 . Given that a large number of patients treated with crizotinib are young adults who will be on therapy for relatively long periods of time, such symptoms can be even more distressing.…”

Section: Hypogonadismmentioning

confidence: 99%

Managing Treatment–Related Adverse Events Associated with Alk Inhibitors

Rothenstein

Letarte

2014

Current Oncology

View full text Add to dashboard Cite

Anaplastic lymphoma kinase (ALK) rearrangements have been identified as key oncogenic drivers in a small subset of non-small-cell lung cancers (xnsclcs). Small-molecule Alk kinase inhibitors such as crizotinib have transformed the natural history of nsclc for this subgroup of patients. Because of the prevalence of nsclc, ALK-positive patients represent an important example of the paradigm for personalized medicine. Although Alk inhibitors such as crizotinib are well tolerated, there is a potential for adverse events to occur. Proactive monitoring, treatment, and education concerning those adverse events will help to optimize the therapeutic index of the drugs. The present review summarizes the management of treatment-related adverse events that can arise with Alk inhibitors such as crizotinib.

show abstract

Testosterone Levels and Quality of Life in Diverse Male Patients With Cancers Unrelated to Androgens

Cited by 26 publications

References 37 publications

Evaluation of an informational pamphlet on distress and perceptions of supportive care for men with prostate cancer

Evaluation of an informational pamphlet on distress and perceptions of supportive care for men with prostate cancer

Testosterone and mortality

Managing Treatment–Related Adverse Events Associated with Alk Inhibitors

Contact Info

Product

Resources

About